Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.
GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GIUp to $440.0 million in milestone payments eligible to be e ...
Gene-editing technologies show great promise for medical treatments and research, with the potential to cure thousands of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback